Management of cutaneous tuberculosis
Cutaneous tuberculosis (TB) is an extrapulmonary form of tuberculosis, which may be classified based on the immunologic state of the host. Chemotherapy still remains the treatment of choice. The management of cutaneous TB follows the same guidelines as that of TB of other organs, which can be treate...
Gespeichert in:
| Veröffentlicht in: | Dermatologic therapy 2008-05, Vol.21 (3), p.154-161 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 161 |
|---|---|
| container_issue | 3 |
| container_start_page | 154 |
| container_title | Dermatologic therapy |
| container_volume | 21 |
| creator | Handog, Evangeline B Gabriel, Teresita G. Pineda, Rosario Trinidad V |
| description | Cutaneous tuberculosis (TB) is an extrapulmonary form of tuberculosis, which may be classified based on the immunologic state of the host. Chemotherapy still remains the treatment of choice. The management of cutaneous TB follows the same guidelines as that of TB of other organs, which can be treated with a short course four‐agent chemotherapeutic regimen given for 2 months followed by a two‐drug regimen for the next 4 months. This chapter highlights current treatment recommendations for cutaneous TB. The important factors to consider in the choice of optimal treatment includes the type of cutaneous involvement, stage of the disease, level of immunity, and general condition of the patient. The highest priority in any cutaneous TB control program is the proper, accurate, and rapid detection of cases and the availability of chemotherapy to all tuberculosis patients until cure. Contact tracing is also an important component of efficient tuberculosis control. |
| doi_str_mv | 10.1111/j.1529-8019.2008.00186.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_19553655</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19553655</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4356-db146e622fac7557b05a17c4da13d7328b9a2ae9bc66c30f7bb7b9a5f8aeb05c3</originalsourceid><addsrcrecordid>eNqNkF1LwzAUhoMobk7_gvRCvGvNR5M04I1suilTESZ6F5I0lc52nU2L2783tWPeGgg5JM97TngACBCMkF9XywhRLMIEIhFhCJMIQpSwaHMAhvuHQ18TwUKIBRuAE-eWHsKCoGMwQAllMY7pEFw8qpX6sKVdNUGVBaZt1MpWrQuaVtvatEXlcncKjjJVOHu2O0fg9e52MZ6F8-fp_fhmHpqYUBamGsXMMowzZTilXEOqEDdxqhBJOcGJFgorK7RhzBCYca25v6JZoqxnDRmBy77vuq6-WusaWebO2KLo_ySRoJQwv0cg6UFTV87VNpPrOi9VvZUIys6QXMpOhOxEyM6Q_DUkNz56vpvR6tKmf8GdEg9c98B3XtjtvxvLyWLmCx8P-3juGrvZx1X9KRknnMq3p6mcxC_4ffpA5Jz8AMakgwo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19553655</pqid></control><display><type>article</type><title>Management of cutaneous tuberculosis</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Handog, Evangeline B ; Gabriel, Teresita G. ; Pineda, Rosario Trinidad V</creator><creatorcontrib>Handog, Evangeline B ; Gabriel, Teresita G. ; Pineda, Rosario Trinidad V</creatorcontrib><description>Cutaneous tuberculosis (TB) is an extrapulmonary form of tuberculosis, which may be classified based on the immunologic state of the host. Chemotherapy still remains the treatment of choice. The management of cutaneous TB follows the same guidelines as that of TB of other organs, which can be treated with a short course four‐agent chemotherapeutic regimen given for 2 months followed by a two‐drug regimen for the next 4 months. This chapter highlights current treatment recommendations for cutaneous TB. The important factors to consider in the choice of optimal treatment includes the type of cutaneous involvement, stage of the disease, level of immunity, and general condition of the patient. The highest priority in any cutaneous TB control program is the proper, accurate, and rapid detection of cases and the availability of chemotherapy to all tuberculosis patients until cure. Contact tracing is also an important component of efficient tuberculosis control.</description><identifier>ISSN: 1396-0296</identifier><identifier>EISSN: 1529-8019</identifier><identifier>DOI: 10.1111/j.1529-8019.2008.00186.x</identifier><identifier>PMID: 18564245</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject>Adult ; Antitubercular Agents - administration & dosage ; Antitubercular Agents - adverse effects ; Child ; cutaneous tuberculosis ; Drug Administration Schedule ; Drug Resistance, Bacterial ; Drug Therapy, Combination ; Female ; Humans ; Immunocompromised Host ; Infant ; Male ; management ; Middle Aged ; Mycobacterium ; Patient Compliance ; Risk Factors ; Skin - pathology ; tuberculosis ; Tuberculosis, Cutaneous - diagnosis ; Tuberculosis, Cutaneous - drug therapy ; Tuberculosis, Cutaneous - epidemiology ; Tuberculosis, Cutaneous - immunology</subject><ispartof>Dermatologic therapy, 2008-05, Vol.21 (3), p.154-161</ispartof><rights>Copyright © Blackwell Publishing, Inc., 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4356-db146e622fac7557b05a17c4da13d7328b9a2ae9bc66c30f7bb7b9a5f8aeb05c3</citedby><cites>FETCH-LOGICAL-c4356-db146e622fac7557b05a17c4da13d7328b9a2ae9bc66c30f7bb7b9a5f8aeb05c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1529-8019.2008.00186.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1529-8019.2008.00186.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18564245$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Handog, Evangeline B</creatorcontrib><creatorcontrib>Gabriel, Teresita G.</creatorcontrib><creatorcontrib>Pineda, Rosario Trinidad V</creatorcontrib><title>Management of cutaneous tuberculosis</title><title>Dermatologic therapy</title><addtitle>Dermatol Ther</addtitle><description>Cutaneous tuberculosis (TB) is an extrapulmonary form of tuberculosis, which may be classified based on the immunologic state of the host. Chemotherapy still remains the treatment of choice. The management of cutaneous TB follows the same guidelines as that of TB of other organs, which can be treated with a short course four‐agent chemotherapeutic regimen given for 2 months followed by a two‐drug regimen for the next 4 months. This chapter highlights current treatment recommendations for cutaneous TB. The important factors to consider in the choice of optimal treatment includes the type of cutaneous involvement, stage of the disease, level of immunity, and general condition of the patient. The highest priority in any cutaneous TB control program is the proper, accurate, and rapid detection of cases and the availability of chemotherapy to all tuberculosis patients until cure. Contact tracing is also an important component of efficient tuberculosis control.</description><subject>Adult</subject><subject>Antitubercular Agents - administration & dosage</subject><subject>Antitubercular Agents - adverse effects</subject><subject>Child</subject><subject>cutaneous tuberculosis</subject><subject>Drug Administration Schedule</subject><subject>Drug Resistance, Bacterial</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Humans</subject><subject>Immunocompromised Host</subject><subject>Infant</subject><subject>Male</subject><subject>management</subject><subject>Middle Aged</subject><subject>Mycobacterium</subject><subject>Patient Compliance</subject><subject>Risk Factors</subject><subject>Skin - pathology</subject><subject>tuberculosis</subject><subject>Tuberculosis, Cutaneous - diagnosis</subject><subject>Tuberculosis, Cutaneous - drug therapy</subject><subject>Tuberculosis, Cutaneous - epidemiology</subject><subject>Tuberculosis, Cutaneous - immunology</subject><issn>1396-0296</issn><issn>1529-8019</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkF1LwzAUhoMobk7_gvRCvGvNR5M04I1suilTESZ6F5I0lc52nU2L2783tWPeGgg5JM97TngACBCMkF9XywhRLMIEIhFhCJMIQpSwaHMAhvuHQ18TwUKIBRuAE-eWHsKCoGMwQAllMY7pEFw8qpX6sKVdNUGVBaZt1MpWrQuaVtvatEXlcncKjjJVOHu2O0fg9e52MZ6F8-fp_fhmHpqYUBamGsXMMowzZTilXEOqEDdxqhBJOcGJFgorK7RhzBCYca25v6JZoqxnDRmBy77vuq6-WusaWebO2KLo_ySRoJQwv0cg6UFTV87VNpPrOi9VvZUIys6QXMpOhOxEyM6Q_DUkNz56vpvR6tKmf8GdEg9c98B3XtjtvxvLyWLmCx8P-3juGrvZx1X9KRknnMq3p6mcxC_4ffpA5Jz8AMakgwo</recordid><startdate>200805</startdate><enddate>200805</enddate><creator>Handog, Evangeline B</creator><creator>Gabriel, Teresita G.</creator><creator>Pineda, Rosario Trinidad V</creator><general>Blackwell Publishing Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope></search><sort><creationdate>200805</creationdate><title>Management of cutaneous tuberculosis</title><author>Handog, Evangeline B ; Gabriel, Teresita G. ; Pineda, Rosario Trinidad V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4356-db146e622fac7557b05a17c4da13d7328b9a2ae9bc66c30f7bb7b9a5f8aeb05c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Antitubercular Agents - administration & dosage</topic><topic>Antitubercular Agents - adverse effects</topic><topic>Child</topic><topic>cutaneous tuberculosis</topic><topic>Drug Administration Schedule</topic><topic>Drug Resistance, Bacterial</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Humans</topic><topic>Immunocompromised Host</topic><topic>Infant</topic><topic>Male</topic><topic>management</topic><topic>Middle Aged</topic><topic>Mycobacterium</topic><topic>Patient Compliance</topic><topic>Risk Factors</topic><topic>Skin - pathology</topic><topic>tuberculosis</topic><topic>Tuberculosis, Cutaneous - diagnosis</topic><topic>Tuberculosis, Cutaneous - drug therapy</topic><topic>Tuberculosis, Cutaneous - epidemiology</topic><topic>Tuberculosis, Cutaneous - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Handog, Evangeline B</creatorcontrib><creatorcontrib>Gabriel, Teresita G.</creatorcontrib><creatorcontrib>Pineda, Rosario Trinidad V</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Dermatologic therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Handog, Evangeline B</au><au>Gabriel, Teresita G.</au><au>Pineda, Rosario Trinidad V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of cutaneous tuberculosis</atitle><jtitle>Dermatologic therapy</jtitle><addtitle>Dermatol Ther</addtitle><date>2008-05</date><risdate>2008</risdate><volume>21</volume><issue>3</issue><spage>154</spage><epage>161</epage><pages>154-161</pages><issn>1396-0296</issn><eissn>1529-8019</eissn><abstract>Cutaneous tuberculosis (TB) is an extrapulmonary form of tuberculosis, which may be classified based on the immunologic state of the host. Chemotherapy still remains the treatment of choice. The management of cutaneous TB follows the same guidelines as that of TB of other organs, which can be treated with a short course four‐agent chemotherapeutic regimen given for 2 months followed by a two‐drug regimen for the next 4 months. This chapter highlights current treatment recommendations for cutaneous TB. The important factors to consider in the choice of optimal treatment includes the type of cutaneous involvement, stage of the disease, level of immunity, and general condition of the patient. The highest priority in any cutaneous TB control program is the proper, accurate, and rapid detection of cases and the availability of chemotherapy to all tuberculosis patients until cure. Contact tracing is also an important component of efficient tuberculosis control.</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><pmid>18564245</pmid><doi>10.1111/j.1529-8019.2008.00186.x</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1396-0296 |
| ispartof | Dermatologic therapy, 2008-05, Vol.21 (3), p.154-161 |
| issn | 1396-0296 1529-8019 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_19553655 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Antitubercular Agents - administration & dosage Antitubercular Agents - adverse effects Child cutaneous tuberculosis Drug Administration Schedule Drug Resistance, Bacterial Drug Therapy, Combination Female Humans Immunocompromised Host Infant Male management Middle Aged Mycobacterium Patient Compliance Risk Factors Skin - pathology tuberculosis Tuberculosis, Cutaneous - diagnosis Tuberculosis, Cutaneous - drug therapy Tuberculosis, Cutaneous - epidemiology Tuberculosis, Cutaneous - immunology |
| title | Management of cutaneous tuberculosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T11%3A16%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20cutaneous%20tuberculosis&rft.jtitle=Dermatologic%20therapy&rft.au=Handog,%20Evangeline%20B&rft.date=2008-05&rft.volume=21&rft.issue=3&rft.spage=154&rft.epage=161&rft.pages=154-161&rft.issn=1396-0296&rft.eissn=1529-8019&rft_id=info:doi/10.1111/j.1529-8019.2008.00186.x&rft_dat=%3Cproquest_cross%3E19553655%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19553655&rft_id=info:pmid/18564245&rfr_iscdi=true |